Quantcast

Latest WOMAC Stories

2014-08-18 08:28:51

ENGLEWOOD, Colo., Aug. 18, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the 6 weeks results of the open label portion of the multiple injections of Ampion(TM) into the knees of patients (n=7) with osteoarthritis (OA). http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Vaughan Clift, MD, Ampio's Chief Regulatory Officer explained: "This first part of the multiple injection study involved patients receiving a series of three 4ml injections...

2014-08-05 08:33:56

ENGLEWOOD, Colo., Aug. 5, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the one month results of the open label portion of the multiple injections of Ampion(TM) into the knees of patients (n=7) with osteoarthritis (OA). http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Vaughan Clift, MD, Ampio's Chief Regulatory Officer explained "This first part of the multiple injections study involved patients receiving a series of three 4ml injections...

2014-07-15 23:14:33

Achieve is conducting a Phase III, randomized, placebo-controlled study to evaluate the safety and effectiveness of a new viscoelastic hydrogel, for the treatment of osteoarthritis of the knee. Birmingham, AL (PRWEB) July 15, 2014 *To see if you qualify for this OA Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you may receive...

2014-06-30 08:30:15

GREENWOOD VILLAGE, Colo., June 30, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has started patient enrollment for the MULTIPLE INJECTIONS STUDY using Ampion(TM) for patients with mostly severe or very severe osteoarthritis (mostly severe Kellgren-Lawrence grade 3 and 4) of the knee for which there is no current non-surgical therapy. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Ampio's CEO, Mike Macaluso, explained, "This study is...

2014-05-14 08:31:36

FREDERICK, Md., May 14, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today announced more detail on the interim results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch® Therapy. The interim results are now published online at the EULAR (European League against Arthritis) conference website at https://b-com.mci-group.com/AbstractList/EULAR2014.aspx...

2014-03-12 20:24:24

DANIA BEACH, Fla., March 12, 2014 /PRNewswire/ -- OrthoSensor, Inc., the leader in Intelligent Orthopaedics, today announced that one-year results of the VERASENSE Multicenter Evaluation were first presented during the American Academy of Orthopaedic Surgeons (AAOS) 2014 Annual Meeting in New Orleans, LA. http://photos.prnewswire.com/prnvar/20140312/FL82401 Dr. Kenneth Gustke, Florida Orthopaedic Institute Adult Reconstruction Surgeon and a lead investigator for the multicenter evaluation,...

2014-03-11 23:33:10

Avail is conducting a Phase 2, randomized, placebo-controlled clinical research study to evaluate the safety and efficacy of an experimental ointment for qualified participants with primary osteoarthritis (OA) affecting a single knee joint. DeLand, FL (PRWEB) March 11, 2014 *To see if you qualify for this Osteoarthritis Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related